Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 28 November, 2000

XTL Biopharm Ltd

Stmnt re Issuance of Patent

XTL Biopharmaceuticals Limited
28 November 2000


-Patent Covers Antibodies Directed Against Hepatitis B Virus Surface Antigen-

Rehovot, Israel and New Ipswich, N.H., November 28, 2000 - XTL
Biopharmaceuticals Ltd. ('XTL') (LSE: XTL) announces that it has been issued
US Patent No. 6,146,629, (the ''629 patent') entitled, 'Human Monoclonal
Antibody Against Hepatitis B Virus Surface Antigen (HBVsAg).' This patent,
XTL's first for a specific antibody, covers human monoclonal antibodies
('MAbs') directed against the hepatitis B virus ('HBV') surface antigen
('HbsAg'). In addition, the patent covers pharmaceutical compositions for the
treatment of HBV infection containing the antibodies. These antibodies can be
given either as monotherapy or in combination with additional anti-viral

'The issuance of the '629 patent is an indication that XTL is gaining
prominence in the realm of human monoclonal antibody therapeutics to treat
infectious disease,' stated Mirit Lotan, PhD, Director of Patents and
Technology Assessment for XTL. 'XTL's therapeutic pipeline for HBV has shown
promising early trial results. This patent issuance is a positive move forward
in building our intellectual property base in monoclonal antibody therapy to
treat HBV.'

The anti-HbsAg antibodies covered by the '629 patent form part of XTL's
product XTL-001, which is undergoing clinical trials in chronic hepatitis B
infected patients. XTL-001, a combination of two high affinity human
monoclonal antibodies, is directed against two different epitopes of HbsAg and
binds to all major HBV subtypes. The antibody pair recognises different areas
of the virus as well as a wide range of viral sero types. XTL-001 was
discovered using Trimera HMAb generation technology and validated and
optimised using the Trimera model technology. Trimera is XTL's patented method
for introducing functional human tissue into mice.

XTL is developing therapeutics to treat hepatitis B, hepatitis C and other
infectious diseases using human monoclonal antibodies and synthetic chemical
products. XTL's competitive advantage lies in its proprietary Trimera
technology, which enables XTL to accelerate its internal product development
and to secure rights to drug candidates and other technology from third
parties. For more information about XTL, visit XTL's website at
XTL Biopharmaceuticals Ltd

Dr Martin Becker, Chief Executive Officer             Tel: +972 (0) 8 940 5134
Glenn Kazo, General Manager & Chief Business Officer  Tel: +1 603 878 9857

Financial Dynamics
David Yates / Sarah Mehanna                           Tel: +44 (0) 20 7269 7236


a d v e r t i s e m e n t